Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Tyra Biosciences Inc (TYRA)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/30/2025: TYRA (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
8 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $30.14
1 Year Target Price $30.14
| 6 | Strong Buy |
| 2 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -69.98% | Avg. Invested days 18 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/30/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 483.92M USD | Price to earnings Ratio - | 1Y Target Price 30.14 |
Price to earnings Ratio - | 1Y Target Price 30.14 | ||
Volume (30-day avg) 8 | Beta 1.07 | 52 Weeks Range 6.42 - 29.60 | Updated Date 06/29/2025 |
52 Weeks Range 6.42 - 29.60 | Updated Date 06/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.63 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -19% | Return on Equity (TTM) -27.04% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 172694048 | Price to Sales(TTM) - |
Enterprise Value 172694048 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -6.95 | Shares Outstanding 53178000 | Shares Floating 14033672 |
Shares Outstanding 53178000 | Shares Floating 14033672 | ||
Percent Insiders 3.69 | Percent Institutions 109.09 |
Analyst Ratings
Rating 3 | Target Price 30.14 | Buy 2 | Strong Buy 6 |
Buy 2 | Strong Buy 6 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Tyra Biosciences Inc
Company Overview
History and Background
Tyra Biosciences Inc. was founded in 2018. It focuses on developing precision medicines to overcome tumor resistance and improve outcomes for cancer patients. The company has advanced multiple programs into clinical development since its inception.
Core Business Areas
- Oncology Drug Development: Focuses on developing small molecule inhibitors for genetically defined cancers.
Leadership and Structure
The company is led by a management team with experience in oncology drug development and business strategy. The organizational structure is typical of a biotech company, with distinct departments for research, development, clinical operations, and business development.
Top Products and Market Share
Key Offerings
- TYRA-300: TYRA-300 is an investigational selective inhibitor of fibroblast growth factor receptor (FGFR) being developed for metastatic urothelial cancer and other FGFR-altered solid tumors. Clinical trials are ongoing. Competitors include existing FGFR inhibitors and other emerging therapies. Market share data is currently unavailable.
- Next Generation RET Inhibitors: Tyra Biosciences is developing novel RET inhibitors that target resistance mutations. Clinical trials are in early stages. Competitors include approved RET inhibitors such as selpercatinib (Retevmo) and pralsetinib (Gavreto). Market share data is currently unavailable.
Market Dynamics
Industry Overview
The oncology market is a large and rapidly growing market, driven by increasing cancer incidence and advancements in targeted therapies. The market is characterized by intense competition and a high degree of innovation.
Positioning
Tyra Biosciences is positioned as a precision oncology company focused on overcoming drug resistance. Its competitive advantage lies in its ability to design and develop novel small molecule inhibitors that target specific genetic alterations.
Total Addressable Market (TAM)
The TAM for targeted oncology therapies is estimated to be in the tens of billions of dollars. Tyra Biosciences is positioned to capture a portion of this market through the successful development and commercialization of its pipeline.
Upturn SWOT Analysis
Strengths
- Novel drug discovery platform
- Experienced management team
- Strong intellectual property portfolio
- Focus on overcoming drug resistance
Weaknesses
- Limited clinical data
- Dependence on successful clinical trial outcomes
- High cash burn rate
- No approved products
Opportunities
- Partnerships with larger pharmaceutical companies
- Expansion of pipeline into new cancer targets
- Accelerated regulatory pathways
- Growing demand for personalized cancer therapies
Threats
- Clinical trial failures
- Competition from established pharmaceutical companies
- Regulatory hurdles
- Patent challenges
Competitors and Market Share
Key Competitors
- LLY
- BLU
- AVXL
Competitive Landscape
Tyra Biosciences competes with both established pharmaceutical companies and other biotech companies developing targeted oncology therapies. It needs to demonstrate improved efficacy or safety compared to existing therapies.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is characterized by preclinical research and clinical trial initiation.
Future Projections: Future growth is dependent on clinical trial success and potential regulatory approvals. Analyst estimates vary based on clinical data and market potential.
Recent Initiatives: Recent initiatives include advancing TYRA-300 into later-stage clinical trials and expanding the RET inhibitor program.
Summary
Tyra Biosciences is a clinical-stage biotech company focused on developing precision oncology therapies. Its strength lies in its novel drug discovery platform and experienced management team. The company faces risks associated with clinical trial outcomes and competition. Successful clinical trials and potential partnerships could drive future growth.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Analyst reports
Disclaimers:
This analysis is for informational purposes only and does not constitute investment advice. Information is based on available public data and may be subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Tyra Biosciences Inc
Exchange NASDAQ | Headquaters Carlsbad, CA, United States | ||
IPO Launch date 2021-09-15 | Co-Founder, President, CEO, Secretary, Treasurer & Director Dr. Todd Harris Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 60 | Website https://tyra.bio |
Full time employees 60 | Website https://tyra.bio | ||
Tyra Biosciences, Inc., a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions. Its lead product candidate is TYRA-300, which is in clinical trials for the treatment of patients with metastatic urothelial carcinoma and other solid tumors. The company is also developing TYRA-300 for skeletal conditions, including achondroplasia, hypochondroplasia, thanatophoric dysplasia, and other FGFR3-driven genetic syndromes; TYRA-200, a candidate in clinical trial for bile duct and solid tumors; and TYRA-430 for the treatment of hepatocellular carcinoma. The company was incorporated in 2018 and is headquartered in Carlsbad, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.